Compounds > ap26113
Page last updated: 2024-08-03 20:48:15

ap26113

Description

Cross-References

ID SourceID
PubMed CID57390074
CHEMBL ID3397300
SCHEMBL ID11916416
MeSH IDM000606712

Synonyms (46)

Synonym
bdbm50062357
chembl3397300 ,
ap26113
SCHEMBL11916416
alk-in-1
HY-13464
CS-1368
1197958-12-5
S7000
(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
c26h34cln6o2p
5-chloro-2-n-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-n-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine
unii-3dgd69c6pv
2,4-pyrimidinediamine, 5-chloro-n2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-n4-(2-(dimethylphosphinyl)phenyl)-
3DGD69C6PV ,
5-chloro-n2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-n4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine
AC-27470
FT-0696829
AKOS025401944
DTXSID30725416
5-chloro-n2-[4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl]-n4-[2-(dimethylphosphinyl)phenyl]-2,4-pyrimidinediamine
EX-A770
ap26113;alk-in-1
HMS3652H14
AS-75104
5-chloro-n2-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-n4-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine
2,4-pyrimidinediamine, 5-chloro-n2-[4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl]-n4-[2-(dimethylphosphinyl)phenyl]-
5-chloro-n2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-n4-(2-(dimethylphosphoryl)phenyl)pyrimidine-2,4-diamine
mfcd23704187
NCGC00351602-09
NCGC00351602-05
SW219566-1
brigatinib(ap26113)
5-chloro-n~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-n~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine
e5j ,
AKOS032949980
BCP06648
Q4653190
SB16487
HMS3673I09
CCG-264698
nsc-800977
nsc800977
nsc-776763
nsc776763
NCGC00351602-02

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.2082AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency23.9185AID1645841
GVesicular stomatitis virusPotency8.4866AID1645842
Interferon betaHomo sapiens (human)Potency2.2778AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency8.4866AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency8.4866AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency8.4866AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)IC500.0660AID1801919
Epidermal growth factor receptorHomo sapiens (human)GI500.0591AID1372112
Insulin receptorHomo sapiens (human)IC500.1000AID1310803
Insulin-like growth factor 1 receptorHomo sapiens (human)IC500.0032AID1310802
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)IC500.0019AID1191196
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)IC500.3965AID1267028; AID1267029; AID1267030; AID1267031; AID1267032; AID1267034
ALK tyrosine kinase receptorHomo sapiens (human)IC500.2975AID1191197; AID1267028; AID1267029; AID1267030; AID1267031; AID1267032; AID1267034; AID1310801

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Aurora kinase AHomo sapiens (human)Kd0.3341AID1342794

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1267031Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267047Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267028Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267044Antiproliferative activity against human DFCI114 cells expressing EML4-ALK G1269A mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1310805Antiproliferative activity against human ALK-negative U937 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804		Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
AID1267033Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267043Antiproliferative activity against human DFCI76 cells expressing EML4-ALK L1152R mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1915686Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay2021European journal of medicinal chemistry, Jan-15, Volume: 210ISSN: 1768-3254The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
AID1267036Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267035Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267034Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1191196Inhibition of ROS1 (unknown origin)2015European journal of medicinal chemistry, Jan-27, Volume: 90ISSN: 1768-3254Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
AID1372112Inhibition of human EGFR del19/T790M/C797S mutant expressed in mouse Ba/F3 cells assessed as cell growth inhibition after 72 hrs by CellTiter-Glo assay2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
ISSN: 1520-4804		Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
AID1267045Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267052Antiproliferative activity against human SK-N-BE(2) cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1191197Inhibition of ALK (unknown origin)2015European journal of medicinal chemistry, Jan-27, Volume: 90ISSN: 1768-3254Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
AID1267037Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1310803Inhibition of human InsR using myelin basic protein as substrate and [gamma-33P]ATP measured after 1 hr2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804		Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
AID1267054Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267050Antiproliferative activity against human SMS-KCNR cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267030Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267048Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267049Antiproliferative activity against human LAN5 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1310804Antiproliferative activity against human ALK-positive KARPAS299 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804		Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
AID1267032Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267042Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1310802Inhibition of human IGF1R using KKKSPGEYVNIEFG as substrate and [gamma-33P]ATP measured after 1 hr2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804		Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
AID1267053Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267029Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1267051Antiproliferative activity against human CHLA20 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1915687Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay2021European journal of medicinal chemistry, Jan-15, Volume: 210ISSN: 1768-3254The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
AID1310801Inhibition of human ALK using poly[Glu:Tyr] (4:1) as substrate and [gamma-33P]ATP measured after 1 hr2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804		Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
AID1267046Antiproliferative activity against human LAN1 cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
ISSN: 1520-4804		Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1801919Kinase Assay from Article 10.1021/acschembio.5b00940: \\Structural and Functional Analysis of the Allosteric Inhibition of IRE1a with ATP-Competitive Ligands.\\2016ACS chemical biology, 08-19, Volume: 11, Issue:8
ISSN: 1554-8937		Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (60.00)24.3611
2020's4 (40.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pyrazolanthrone
1
anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector		201620168.0low000010
sb 415286
1
C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent		201620168.0low000010
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone
1
benzamides;
N-acylpiperidine		201620168.0low000010
bms345541
1
quinoxaline derivative201620168.0low000010
tae226
1
morpholines201620168.0low000010
ap23464
1
201620168.0medium000010
crenolanib
1
aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201620168.0low000010
azd 7762
1
aromatic amide;
thiophenes		201620168.0low000010
crizotinib
3
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201520168.7medium000030
nvp-tae684
5
piperidines201520216.8high000041
tg101209
1
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		201620168.0low000010
asp3026
2
aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor		201820214.5medium000011
gsk 1363089
1
aromatic ether201520159.0low000010
thiopental sodium
1
organochlorine compound;
piperazines;
pyrimidines		antineoplastic agent;
tyrosine kinase inhibitor		201820186.0low000010
alectinib
1
aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201520159.0low000010
AZD3463
3
aminopiperidine;
aminopyrimidine;
indoles;
monomethoxybenzene;
organochlorine compound;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201620215.7high000021
ceritinib
4
aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201520216.5medium000031
hesperadin
1
201620168.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Cancer of Lung0
4
201520216.5medium000031
Carcinoma, Non-Small Cell Lung0
4
201520216.5medium000031
Carcinoma, Non-Small-Cell Lung0
4
201520216.5medium000031
Congenital Zika Syndrome0
1
202020204.0low000010
Disease Models, Animal0
1
202020204.0low000010
Experimental Neoplasms0
1
201620168.0low000010
Lung Neoplasms0
4
201520216.5medium000031
Neuroblastoma0
1
201520159.0low000010
Zika Virus Infection0
1
202020204.0low000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019

Dosage (1)

ArticleYear
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23		2015